Literature DB >> 8087192

Intravenous gammaglobulin: pharmacology, clinical uses and mechanisms of action.

R I Schiff1.   

Abstract

Mesh：

Substances：

Year:  1994        PMID： 8087192     DOI： 10.1111/j.1399-3038.1994.tb00222.x

Source DB:  PubMed          Journal:  Pediatr Allergy Immunol        ISSN： 0905-6157            Impact factor:   6.377


× No keyword cloud information.
  7 in total

1.  Multicenter crossover comparison of the safety and efficacy of Intraglobin-F with Gamimune-N, Sandoglobulin, and Gammagard in patients with primary immunodeficiency diseases.

Authors:  R I Schiff; L W Williams; R P Nelson; R H Buckley; W Burks; R A Good
Journal:  J Clin Immunol       Date:  1997-01       Impact factor: 8.317

2.  Suppression of allo-human leucocyte antigen (HLA) antibodies secreted by B memory cells in vitro: intravenous immunoglobulin (IVIg) versus a monoclonal anti-HLA-E IgG that mimics HLA-I reactivities of IVIg.

Authors:  D Zhu; M H Ravindranath; P I Terasaki; T Miyazaki; T Pham; V Jucaud
Journal:  Clin Exp Immunol       Date:  2014-08       Impact factor: 4.330

3.  Antibody-based protection of gnotobiotic piglets infected with Escherichia coli O157:H7 against systemic complications associated with Shiga toxin 2.

Authors:  A Donohue-Rolfe; I Kondova; J Mukherjee; K Chios; D Hutto; S Tzipori
Journal:  Infect Immun       Date:  1999-07       Impact factor: 3.441

Review 4.  Efficacy of Intravenous Immunoglobulin in Neurological Diseases.

Authors:  Jan D Lünemann; Isaak Quast; Marinos C Dalakas
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

5.  Safety, efficacy and pharmacokinetics of a new 10% liquid intravenous immunoglobulin (IVIG) in patients with primary immunodeficiency.

Authors:  Richard L Wasserman; Joseph A Church; Mark Stein; James Moy; Martha White; Steven Strausbaugh; Harry Schroeder; Mark Ballow; James Harris; Isaac Melamed; David Elkayam; William Lumry; Daniel Suez; Syed M Rehman
Journal:  J Clin Immunol       Date:  2012-03-06       Impact factor: 8.317

Review 6.  Review of intravenous immunoglobulin replacement therapy trials for primary humoral immunodeficiency patients.

Authors:  H W Schroeder; C J Dougherty
Journal:  Infection       Date:  2012-09-12       Impact factor: 3.553

Review 7.  Intravenous immunoglobulins: evolution of commercial IVIG preparations.

Authors:  John A Hooper
Journal:  Immunol Allergy Clin North Am       Date:  2008-11       Impact factor: 3.479
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.